A calcium blocking and anticholinergic agent (terodiline) in the treatment of detrusor hyperreflexia: a placebo-controlled, cross-over trial.

AUTOR(ES)

Petersen, T

RESUMO

In 25 neurological patients with detrusor hyperreflexia terodiline reduced the number of total micturitions during daytime. Bladder capacity was increased and amplitude of the bladder contractions was reduced. An increase in residual urine was also observed. Mild anticholinergic side-effects were measured on pupillary motility and on heart rate variation. It is concluded that terodiline is a useful alternative in treatment of patients with detrusor hyperreflexia.

Documentos Relacionados

• Assessment of single-dose benzodiazepines on insulin secretion, insulin sensitivity and glucose effectiveness in healthy volunteers: a double-blind, placebo-controlled, randomized cross-over trial [ISRCTN08745124]
• Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial.
• Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study
• Proceedings: Effects of natural oestrogens on blood clotting--a double-blind cross-over trial.
• S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]